MRSA

This In the Literature piece explores if we can mitigate some of the adverse reactions that are being seen in obese patients who receive vancomycin through AUC-dosing.

The aggregated average HAI rates before and after discontinuing contact precautions were 0.14 and 0.15 MRSA HAI/1000 patient days, 0.06 and 0.04 VRE HAI/1000 patient days, and 0.04 and 0.03 MRSA LabID events/100 admissions.

A new study showed no statistically significant reduction in clinical cultures between chlorhexidine bathing and routine care.

Delafloxacin was comparable to vancomycin/aztreonam in eliminating MRSA at 98.1% versus 98.0%, respectively, at follow-up in 2 pooled phase 3 studies.

A new study of cockroaches collected from an Iranian hospitals sheds light on how these insects can carry and spread resistant microbes.

Post-discharge decolonization education and bioburden reduction could be critical to reducing MRSA infections.

Staph infections aren't going away and now a new report says we're not doing as well as we think.

Ibuprofen succeeded in fighting S aureus in a laboratory setting, although it’s not clear whether the same effect would hold true in patients with systemic infections.

Applying hospital-based outbreak tools helped researchers identify a community MRSA outbreak

Antibiotic cycling is not linked to a reduced incidence of health care-associated MRSA or Clostridium difficile infection, a new study shows.

A collaborative, international effort aims to answer tough antimicrobial resistance questions.

New report highlights risks and costs associated with these infections equal to roughly 1 million deaths and $65 billion in the United States.

Data from a pooled analysis of the REVIVE-1 and 2 studies found iclaprim to be non-inferior to vancomycin based on earl clinical response in patients with wound infections.

A new report from the CDC shows substantial progress on the incidence of health care-associated infections in the United States, but there is still more work to be done.

ID Week 2018 was held October 2-7, 2018, in San Francisco, California. The conference featured results of new studies on a variety of infectious disease topics as well as advancements being made in the field. Here are 5 key takeaways from the meeting.

The combination of daptomycin plus fosfomycin was more effective than daptomycin alone for treating patients with MRSA bacteremia.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Investigators find telavancin has potent in vitro activity and low resistance development potential when used against S aureus isolates in patients with cystic fibrosis.

Additional evidence supports the use of oritavancin as a cost-saving outpatient treatment for acute bacterial skin and skin structure infections (ABSSTIs) in patients who would otherwise be admitted to the hospital for therapy.

Bruce Jones, PharmD, BCPS, discusses the growing burden of ABSSSI and why there have been an influx of MRSA cases.